VEGFA and non-small cell lung carcinoma: Furthermore, analysis of the Impower150 trial showed that EGFR-mutant NSCLC patients treated with a regimen of anti-PD-L1 (atezolizumab), anti-VEGF (bevacizumab), and carboplatin and paclitaxel had a PFS of over 10.2 months with response rate of 71% [12].